No studies have addressed the presence or the prognostic role of EPB41L3 and RASSF2 hypermethylation in diffuse gliomas, and there have been few studies of TSP-1; the hypermethylation of these genes is known to be clinically significant in other types of cancers [6–8]. The gene discussed is RASSF2; the disease is cancer.